Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G's NEW TOP PHARMACEUTICAL EXEC HAS R&D AND DIAPER MARKETING BACKGROUND

Executive Summary

Norwich's new top exec in the P&G (Procter & Gamble) hierarchy is Senior VP Harry Tecklenburg, a 32-year veteran of P&G with seven years of experience heading P&G's research and development efforts and several years in charge of P&G's large disposable diaper products business. Tecklenburg, 53, is assuming responsibility for P&G's Norwich div. (formerly Norwich-Eaton) due to the promotion of Charles Carroll, the current head of P&G's pharmaceutical business. Carroll is moving to VP-Bar Soap and Household Cleaning Products. The management changes become effective June 1. The combination of Tecklenburg's experience during the last 12 years in research and diaper marketing provides a logical background for his new role with Norwich. From his research experience, he should be sensitive to the R&D needs of the OTC and Rx segments. The diaper marketing is one of P&G's current businesses that is related to OTC drugs in many of the outlets of distribution and in regulation. While P&G has not made any major marketing effort in the drug area with Norwich since the purchase, the firm has strongly indicated its interest in the health care segment as a significant profit center in the next decade. Other firms throughout the health care segment are keeping a close eye on P&G to see which way the firm strikes in the health market. At a recent strategic planning conference in the health field, for example, a Pfizer exec noted the potential opening for a consumer marketing company like P&G in the Rx business if direct advertising to the consumer becomes a larger force. Similarly, an exec from C. R. Bard commented on P&G's toehold in the home health care product market with its adult diapers, a category that P&G has been building for over eight years. Under the new P&G management team, Tecklenburg will report to new Vice Chairman Thomas Laco. In addition to "broad responsibility" for the firm's staff functions and P&G's food service product operations, Laco has top oversight of pharmaceuticals. Among P&G's recent quiet R&D efforts in the drug area is sucrose polyester, a zero-calorie fat for weight control in obese, maturity-onset diabetics. The substance may also have applications in the food area. Assuming Laco's current responsibilities as overall head of P&G's U.S. consumer products business, except for Norwich, will be group VP John Pepper, 45, who becomes the lone exec VP at Procter & Gamble. Along with Laco, current exec VP Edwin Artzt has also been promoted to vice chairman. His responsibilities as overall head of P&G's internatl. operations will not change, the firm said.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel